Back to all Portfolio news
November 13, 2013

TissueTech’s Bio-Tissue Introduces the Next Generation of PROKERA Biologic Corneal Bandage Devices

Subsidiary of TissueTech Bio-Tissue, Inc., an ophthalmic biologic therapeutics company, has announced the introduction of two next-generation PROKERA Biologic Corneal Bandage devices. PROKERA is the only Food and Drug Administration (FDA)-cleared therapeutic device that reduces inflammation and promotes scar-less healing.

“We are very pleased to introduce these new PROKERA products and expand the therapeutic options in ocular surface regeneration, across the full spectrum of severity, available to ophthalmologists and their patients,” said Tom Daniells, Chief Commercial Officer of Bio-Tissue™.  “The growing PROKERA family is the culmination of 15 years of clinical experience in more than 150,000 successful human transplantations, backed by 25 years of government-funded research and over 300 peer-reviewed publications.”

Innovative Additions to the PROKERA® Family

New PROKERA SLIM with ComfortRING™ Technology was designed with a slim profile that contours to the ocular surface, moves with the eye, and maximizes amniotic membrane contact with the cornea, limbus, and limbal stem cells, providing  clinical benefits  and maximizing patient comfort.  

“PROKERA SLIM is ideal for mild-to-moderate ocular surface conditions,” said Preeya K. Gupta, MD, Assistant Professor of Ophthalmology at Duke Eye Center.  “This new design facilitates our ability to deliver the benefits of amniotic tissue-mediated active healing to patients with microbial or HSV keratitis, recurrent corneal erosions, or corneal abrasions, with a quick, in-office application.”

New PROKERA PLUS incorporates multiple layers of amniotic membrane that make it suitable for therapeutic applications requiring longer biologic action and durability on the ocular surface.  It is recommended for use in severe indications such as chemical burns, Stevens Johnson Syndrome, and severe corneal ulcers.

Original PROKERA is recommended for patients with moderate to severe indications such as neuropathic PED, severe infectious keratitis, and post-DSEK for bullous keratopathy.

“Bio-Tissue’s PROKERA family of products allows you to match the right therapy to the right patient,” said Neel R. Desai, M.D., Director of Cornea and Refractive Surgery, The Eye Institute of West Florida.  “These new additions to the PROKERA line are truly innovative technology that provides superior therapeutic outcomes and a more optimal patient experience.”